Results A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years – range 14–95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (pA poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p less than .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision).

Conclusion Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with very low fatality rate in patients.

A major Greenland glacier that was one of the fastest shrinking ice and snow masses on Earth is growing again, a new NASA study finds. The Jakobshavn (YA-cob-shawv-en) glacier around 2012 was retreating about 1.8 miles (3 kilometers) and thinning nearly 130 feet (almost 40 meters) annually. But it started growing again at about the same rate in the past two years, according to a study in Mondayâ(TM)s Nature Geoscience. Study authors and outside scientists think this is temporary.